Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 1
Submit an article Journal homepage
10
Views
0
CrossRef citations to date
0
Altmetric
Review

Health status in COPD: current data and future trends

Sabina A Antoniu Clinic of Pulmonary Disease, University of Medicine and Pharmacy. [email protected]
,
Traian Mihaescu Clinic of Pulmonary Disease, University of Medicine and Pharmacy. [email protected]
,
Mauro Carone Clinic of Pulmonary Disease, University of Medicine and Pharmacy. [email protected]
&
Claudio F Donner Clinic of Pulmonary Disease, University of Medicine and Pharmacy. [email protected]
Pages 57-65 | Published online: 09 Jan 2014

References

  • Randall Curtis J, Martin DP, Martin TR. Patient assessed health outcomes in chronic lung disease: what are they, how do they help us and where do we go from here? Am. Respir. Olt. Care. Med 156,1032–1039 (1997).
  • ••Of considerable interest for HS, HRQOLand QoL definitions.
  • Carone M, Jones PW. Health status 'quality of life'. Ear Respir. Mon 13,22–35 (2000).
  • GOLD: Global Strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease NHLBI/ WHO workshop report — Executive Summary. (1998).
  • Murray GJL, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990–2020. In: The Global Buirlen of Disease. Murray GJL, Lopez AD (Fris). Harvard University Press, MA, USA, 361–375 (1996).
  • Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1(6077), 1645–1648 (1977).
  • ERS Consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease. Eur Respir. J. 8,1398–1420 (1995).
  • ATS statement. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Grit. Care. Med. 152(5),s77-s120 (1995).
  • Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann. Int. Med. 118,622–629 (1993).
  • Jones PW Health status measurement in chronic obstructive pulmonary disease. Thomx56, 880–887 (2001). Explains the current role of HS in COPD management.
  • Guyatt GH, King DR, Feeny DH etal. Generic and specific measurement of health related quality of life in a clinical trial of respiratory rehabilitation. J. Gun.43idemiol. 52,187-192 (1999).
  • Stewart AL, Hays RD, Ware JE. The MOS Short Form General Survey: reliability and validity in a patient population. Med. Care. 26,724-732 (1988).
  • Mahler DA, Mackowiak JI. Evaluation of the short form 36-item questionnaire to measure health-related quality of life in patients with COPD. Chest 107,1585–1589 (1995).
  • Griffiths TL, Burr ML, Campbell IA eta]. Results at 1 year of out-patient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 355, 362–368 (2000).
  • Fan V, Curtis JR, Tu SP, McDowell M, Fihn SD. Using quality of life to predict hospitalization and mortality in patients with obstructive lung disease. Chest 122, 429–436 (2002).
  • Brazier JE, Usherwood T, Harper R etal Deriving a preference-based-single index from the UK SF-36 health survey. J. Gun. 43idemiol. 51,1115-1128 (1998).
  • van Schayck CP, Dompeling E, Rutten MP etal The influence of an inhaled steroid on quality of life in patients with asthma and COPD. Chest 107,1199–1205 (1995).
  • Cooper JD, Trulock EP, Triantafillou AN etal Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J. Thorac. Canliovasc. Surg. 109,106-119 (1995). 18Prieto L, Alonso J, Ferrer M eta]. Are results of the SF-36 health survey and the Nottingham Health Profile similar? A comparison in COPD patients. Quality of life in COPD study group. J. Can. 43idemiol. 50,463-473 (1997).
  • Bergner M, Bobitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 19,787–805 (1981).
  • Prigatano GP, Wright EC, Levin D. Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease. Arch. Intern Med 144, 1613–1619 (1984).
  • Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med 93,391–398 (1980).
  • The Eurogol group. Eurogol — a facility for the measurement of health-related quality of life. Health Policy16,199–208 (1990) .
  • Busschbach JJ, Horikx PE, Bosch JJ van den, Brutel de la Riviere de Charro FT Measuring the quality of life before and after bilateral lung transplantation in patients with cystic fibrosis. Chest 105, 911–917 (1994).
  • Harper R, Brazier JE, Waterhouse JC, Walters SJ, Jones NMB, Howard P Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an out-patient setting. Thorax52, 879–887 (1997).
  • Kaplan PM, Atkins CJ, Timms R Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary disease. J. Chron. DA 37,85–95 (1984).
  • Orenstein D, Pattishall E, Nixon P, Ross E, Kaplan R. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest98, 1081–1084 (1990).
  • Guyatt GH, Berman LB, Townsensd M, Pugsley SO, Chambers LW A measure of quality of life for clinical trials in chronic lung disease. Thorax 42, 773–778 (1987).
  • Wikstra PJ, Ten Vergert EM, van Altena R etal Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax 49,465–467 (1994).
  • Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD. Development of a self-reported Chronic Respiratory Questionnaire (CRQ- SR). Thorax56, 954–959 (2001).
  • Jones PW, Quirk FH, Baveystock CM, Littlejohns P A self-complete measure for chronic airflow limitation — the St. George's Respiratory Questionnaire. Am. Rev Respir. Dis. 145,1321–1327 (1992).
  • Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am. J. Respir Crit. Care Med 155,1283–1289 (1997).
  • McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax48, 227–232 (1993).
  • Spencer S, Calverley PM, Sherwood Burge P, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Arn. Respir. Crit. Care Med 163, 122–128 (2001).
  • Casaburi R, Mahler DA, Jones PW etal A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir J. 19,217–224 (2002).
  • Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PN. Randomized controlled trial of pulmonary rehabilitation in patients with severe chronic obstructive pulmonary disease stratified with MRC dyspnoea scale. Eur. Respir J. 12,363–369 (1998).
  • Carone M, Bertolotti G, Donner CF, Jones PW, on behalf of the QuESS group. Mortality in chronic respiratory failure is detected better by health status (QoL). Am. Respir. Crit. Care Med 163, A13 (2001).
  • Weaver TE, Narsavage GL. Physiological and psychological variables related to functional status in chronic obstructive pulmonary disease. NUTS. Res. 41,286–291 (1992).
  • Votto J, Bowen J, Scalise P, Wollschlanger C, ZuWallack R. Short-stay comprehensive in-patients pulmonary rehabilitation for advanced chronic obstructive pulmonary disease. Arch. Phy. Med. Rehabil. 77,1115–1118 (1996).
  • Haggerty M, Stockdale-Wolley R, Rios M, Zu Wallack R. The effects of pulmonary rehabilitation on functional status and exercise tolerance. Am. J. Respir. Crit. Care 151, A683 (1995).
  • Lareau S, Carrieri-Kohlman V, Janson- Bjerklie S, Roos P. Development and testing of the pulmonary functional status and dyspnoea questionnaire (PFSDQ). Heart Lung23, 242–250 (1994).
  • Lareau SC, Breslin EH, Meek PM. Functional status instruments: outcome measure in evaluation of patients with chronic obstructive pulmonary disease. Heart Lung25, 212–224 (1996).
  • Tu SP, McDonell MB, Spertus JA etal. A new self-administered questionnaire to monitor health-related-quality life in patients with COPD. Ambulatory Care Quality Improvement Project (ACQUIP) Investigators. Chest 112,614–622 (1997).
  • Hyland ME, Bott J, Singh S, Kenyon CA. Domains, constructs and development of the breathing problems questionnaire. Qual. Life Res. 3,245–256 (1994).
  • Hyland ME, Singh SJ, Sodergren Sc, Morgan MP. Development of a shortened version of the Breathing Problems Questionnaire suitable for use in a pulmonary rehabilitation clinic, a purpose specific, disease-specific questionnaire. Quail Life Res. 7, 227–233 (1998).
  • Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am. Respir. Grit. Care Med. 157,785–790 (1998).
  • Carone M, Bertolotti G, Anchisi F, Zotti AM, Donner CF, Jones PW and the Quality of Life in Chronic Respiratory Failure Group. Analysis of factors that characterise health impairment in patients with chronic respiratory failure. Eur. Respir. J. 13,1293–1300 (1999).
  • Carone M, Jones PW, on behalf of the QuESS Group. Quality of life evaluation and survival study: a 3-yr prospective multinational study on patients with chronic respiratory failure. Monalcli. Alrh. Chest Dis 56,17–22 (2001).
  • Maille AR, Koning CJ, Zwinderman AH, Willems LN, Dijkman JH, Kaptein AA. The development of the 'Quality of life for respiratory Illness Questionnaire (QOL-RI()) a disease specific quality of life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir. Med 91,297–309 (1997).
  • McSweeny AJ, Grant I, Heaton RK, Adams KM, Timms RM. Life quality of patients with chronic obstructive pulmonary disease. Arch. Intern. Med 142,473–478 (1982).
  • Ketelaars CAJ, Schlosser MAG, Mostert R, Huyer Abu-Saad H, Halfens RJG, Wouters EFM. Determinants of health related quality of life in patients with chronic obstructive pulmonary disease. Thorax 51, 39–43 (1996).
  • Wijkstra PJ, TenVergert EM, van der Mark TW etal. Relation of lung function, maximal inspiratory pressure, quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. Thorax 49, 468–472 (1994).
  • Guyatt GH, Townsend M, Pugsley SO etal Bronchodilators in chronic airflow limitation. Am. Rev Respir Dis. 135,1069–1074 (1987).
  • Dahl R, Greefhorst LAPM, Nowak D, Nonikov V, Byrne AM, della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164,778–784 (2001).
  • Jones PW. Interpreting thresholds for a clinically significant change in health status (quality of life') with treatment for asthma and COPD. Eur Respir. J. 19,398–404 (2002).
  • Vincken W van Noord JA, Greefhorst APM etal, on behalf of the Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr treatment with tiotropium. Eur. Respir. 19,209-216 (2002).
  • Van Schayck CP, Rutten-van Molken MOMH, van Doorslaer EKA etal Two year bronchodilator treatment in patients with mild airflow obstruction. Chest 102,1384–1391 (1992).
  • Mahler DA, Donohue JF, Barbee RA eta]. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115,957–965 (1999).
  • Donohue JF, van Noord JA, Bateman ED etal A 6 month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122,47–55 (2002).
  • Van Schayck CP, Dompeling E, Rutten MP, Folgering H, van den Boom G, van Weel C. The influence of an inhaled steroid on quality of life in patients with asthma and COPD. Chest107,1199–1205 (1995).
  • Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomized double-blind placebo-controlled study of fluticasone propionate in patients with moderate to severe COPD. Br Med. 320,1297–1303 (2000).
  • Spencer S, Calverley PMA, Burge PS, Jones PW Health status deterioration in patients with chronic obstructive pulmonary disease. ATM I Respir. Crit. Cate Med 163, 122–128 (2001).
  • Mahler DA, Wire P, Horstman D etal Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166,1084–1091 (2002).
  • Mahler DA, Matthay, Snider PE, Wells CK, Loke J. Sustained-release theophylline reduce dyspnea in nonreversible obstructive airway disease. Am. Rev Respir. Dis. 131, 22–25 (1985).
  • Murciano D, Auclair MET, Pariente R, Aubier M. A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl. J. Med. 320,1521–1525 (1989).
  • Mahon JL, Laupacis A, Hodder RV etal Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest 115,38–48 (1999).
  • McKay SE, Howie CA, Thomson AH etal. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 48,227–232 (1993).
  • Compton CH, Gubb J, Nieman R etal. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomized, dose-ranging study. Lancet 358,265–270 (2001).
  • Brazier J, Spencer MD, Zhu J. Effect of SGRQ response on health status measured by the SF-6D. Etu: Respir. J. 20,345s (2002).
  • Griffiths TL, Burr ML, Campbell IA et at results at 1 year of out-patient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 355, 362–368 (2000).
  • Ries AL, Kaplan PM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation on physiologic and psychological outcomes in patients with chronic obstructive pulmonary disease. Ann. Intern. Med 122, 823–832 (1995).
  • Goldstein RS, Gort EH, Stubbing D, Avedano MA, Guyatt GH. Randomized controlled trial of respiratory rehabilitation. Lancet 344,1394–1397 (1994).
  • Wijkstra PJ, van der Mark TW, Kraan J, van Altena R, Koete GH, Postma DS. Effects of home rehabilitation on physical performance in patients with chronic obstructive pulmonary disease (COPD). Eur. Respir 9,104–110(1996).
  • Lacasse Y, Wong E, Guyatt GH, King D, Cook DJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 348, 1115–1119 (1996).
  • Report of the Medical Research Council Working Party: Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 318,681–685 (1981).
  • Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic obstructive lung disease. Ann. Intern. Med 93,391–398 (1980).
  • Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. Thorax-51, 44–47 (1996).
  • IPPB Study Group: Intermittent positive pressure breathing therapy of chronic obstructive pulmonary disease: a clinical trial. Arch. Intern. Med 99,612–620 (1983).
  • Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxemia. ELIE Respir. J. 9,2335-2339 (1996).
  • Okubadejo AA, O'Shea L, Jones PW, Wedzicha JA. Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy. Eur. Respirj 10, 1572–2575 (1997).
  • Cooper JD, Patterson GA, Sundaresan RS et al Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J. Thorac. Carcliovasc. Surg. 112,1319-1330 (1996).
  • Cordova F, O'Brien G, Furukawa S, Kuzma AM, Travaline J, Criner GJ. Stability of improvements in exercise performance and quality of life following bilateral lung volume reduction surgery in severe COPD. Chest 112,907–915 (1997).
  • Leyenson V, Furukawa S, Kuzma AM, Cordova F, Travaline J, Criner GJ. Correlations of changes in quality of life after lung volume reduction surgery with changes in lung function, exercise and gas exchange. Chest 118,728–735 (2000).
  • Hamacher J, Buchi S, Georgescu CL et at Improved quality of life after lung volume reduction surgery. Eur Respir. J. 19,54-60 (2002).
  • Criner GJ, Cordova FC, Furukawa S, Kuzma AM, Travaline JM, Leyeson V. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J. Respir. Grit. Care Med. 160,2018–2027 (1999).
  • Moy MJ, Ingenito E, Mentzer SJ, Evans RB, Reilly JJ Jr. Health-related quality of life improves following pulmonary rehabilitation and lung volume reduction surgery. Chest 115,383–389 (1999).
  • Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Grit. Cam Med. 157, 1418–1422 (1998).
  • Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thomx52, 67–71 (1997).
  • Traver GA. Measures of symptoms and life quality to predict emergent use of institutional healthcare resources in chronic obstructive airways disease. Heart Lung17, 689–697 (1988).
  • Eddy DM. Clinical decision making — from theory to practice: anatomy of a decision. JA/V/4 263,441–443 (1990).
  • Griffiths 11, Phillips CJ, Davies S, Burr ML, Campbell LA. Cost effectiveness of an out-patient multidisciplinary pulmonary rehabilitation programme. Thomx56, 779–784 (2001).
  • Casali P, Licitra L, Costantini M eta]. Quality of life assessment and clinical decision making. Ann. Oncol. 8,1207–1211 (1997).

Website

  • American Thoracic Society, Quality of Life Resource. Preferences and Utilities. www.atsqol.orgiutility.asp Accessed January 22,2003.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.